Loading…
Loading…
Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb remains a Strong Buy, trading at a 51% discount to sector median with a compelling risk/reward profile. BMY's growth portfolio delivered 15% YoY revenue growth, offsetting headwinds from Opdivo's decline and upcoming Eliquis patent expiry. The company boasts a 3.7% forward dividend yield, robust margins, and accelerating bottom-line growth, supporting its defensive, income-generating appeal.
Bristol Myers Squibb remains undervalued, trading at a 9.8x forward P/E with a 3.7% yield. BMY's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting 5% YoY total revenue growth. Management raised full-year adjusted EPS guidance, with robust Eliquis growth and a strong pipeline of over 10 potential new medicines.
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Technical indicators have turned bullish for the three stocks.